Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bliss

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2023
ESMO Guidance for Reporting Oncology real-World evidence (GROW)L Castelo-Branco, A Pellat, D Martins-Branco, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
ESMO Guidance for Reporting Oncology real-World evidence (GROW)L Castelo-Branco, A Pellat, D Martins-Branco, et al.
BMC Plant Biology|April 1, 2005
Floral gene resources from basal angiosperms for comparative genomics researchVictor A Albert, Douglas E Soltis, John E Carlson, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 17, 2023
ESMO Guidance for Reporting Oncology real-World evidence (GROW)L Castelo-Branco, A Pellat, D Martins-Branco, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
ESMO Guidance for Reporting Oncology real-World evidence (GROW)L Castelo-Branco, A Pellat, D Martins-Branco, et al.
BMC Plant Biology|April 1, 2005
Floral gene resources from basal angiosperms for comparative genomics researchVictor A Albert, Douglas E Soltis, John E Carlson, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
ESMO Open|October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 10